(BUSINESS WIRE)– Celgene Corporation (NASDAQ:CELG) reported operating results for the fourth quarter and full year of 2014. For the fourth quarter of 2014, net product sales were $2,055 million compared to $1,725 million from the same period in 2013, an increase of 19 percent. Fourth quarter total revenue increased 19 percent to $2,085 million compared to $1,756 million in the fourth quarter of 2013. Adjusted net income for the fourth quarter of 2014 increased 29 percent to $840 million compared to $649 million in the fourth quarter of 2013. For the same period, adjusted diluted earnings per share (EPS) increased 33 percent to $1.01 from $0.76, on a stock split-adjusted basis… Read more »
Shares of Celgene Corporation closed yesterday at $118.97 . CELG has a 1-year high of $124.60 and a 1-year low of $66.85. The stock’s 50-day moving average is $116.17 and it’s 200-day moving average is $101.11.
On the ratings front, Celgene Corporation (NASDAQ:CELG) has been the subject of a number of recent research reports. In a report issued on January 13, Cantor Fitzgerald analyst Mara Goldstein maintained a Buy rating on CELG, with a price target of $131, which represents a potential upside of 10.1% from where the stock is currently trading. Separately, on January 12, J.P. Morgan`s Cory Kasimov reiterated a Hold rating on the stock .
In total, 2 research analysts have assigned a Hold rating and 6 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $118.97 which is 5.6% above where the stock closed yesterday.
Celgene Corp is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.